Study of Clinical Outcomes of Thyroid Cancer

Conditions

Thyroid Neoplasms

Keywords

papillary thyroid cancer, follicular thyroid cancer, poorly differentiated thyroid cancer, anaplastic thyroid cancer, medullary thyroid cancer

Brief summary

The Italian Thyroid Cancer Observatory (ITCO) repository was established to collect data on thyroid cancer management in a prospective and consecutive series of newly-diagnosed patients, enrolled in centers uniformly distributed across the nation.

Detailed description

Little information is available on current practices in the treatment of thyroid cancer: a web-based thyroid cancer database was created to collect real-life data. The participants' network include tertiary referral centers operating at the national level, as well as smaller hospital-based units with local or regional recruitment areas.

De Leo S, Brigante G, D'Elia S, Censi S, Madeo B, Morelli S, Nervo A, Repaci A, Sparano C, Stramazzo I, Virili C, Bertagna F, Dondi F, Puxeddu E, Talpacci E, Zatelli MC, Ambrosio MR, Felicetti F, Piovesan A, Petrone L, Adornato V, Trevisan M, Fugazzola L, Mele C, Zavattaro M, Solaroli E, Salituro N, Rossi M, Pagano L, Colapinto A, Basso C, Ceresini G, Marina M, Crocetti U, Massa M, Deandrea M, Retta F, Spiazzi G, Rolli N, Bruno R, Carbone A, Rotondi M, Magri F, Fallahi P, Chiofalo MG, Santaguida MG, Monti S, Porcelli T, Castello R, Sagnella A, Clausi C, Di Dalmazi G, Tumino D, Palermo A, Brunetti A, Lania A, Liverani A, Durante C, Petrillo UF, Alfo' M, Filetti S, Grani G.

2025-11-012 citations

10.1210/clinem/dgaf190

A Prospective Multicenter Study Examining the Relationship Between Thyroid Cancer Treatment Outcomes and the Presence of Autoimmune Thyroiditis

Simone De Leo, Silvia D'Elia, Giorgio Grani, Francesco Dondi, Francesco Bertagna et al. (41 authors)

Thyroid2023-09-1915 citations

10.1089/thy.2023.0052

A Data-Driven Approach to Refine Predictions of Differentiated Thyroid Cancer Outcomes: A Prospective Multicenter Study

Giorgio Grani, Michele Gentili, Federico Siciliano, Domenico Albano, Valentina Zilioli et al. (45 authors)

The Journal of Clinical Endocrinology & Metabolism2023-02-1626 citations

10.1210/clinem/dgad075

Interventions

PROCEDUREStandard treatment

e.g., surgery, radioiodine therapy, systemic treatments (multikinase inhibitors), surveillance

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

No

Inclusion criteria

* pathologically confirmed thyroid cancer * clinical follow-up including serum thyroglobulin (Tg) assays, circulating Tg antibodies, and high-resolution gray-scale and color Doppler US of the thyroid bed and cervical lymph node compartments. Additional imaging studies and/or fine-needle aspiration biopsy for cytology are ordered at the examiner's discretion in accordance with evidence-based guidelines * entire follow-up at a participating clinical center.

Exclusion criteria

* patients referred to the recruiting centers ≥12 months from the primary treatment

Design outcomes

Primary

Measure	Time frame	Description
Disease persistence or recurrence	Up to 10 years from the primary treatment	Composite event of disease persistence or recurrence during clinical follow-up, detected by any of the available imaging tools (neck sonography, computed tomography \[CT\], magnetic resonance imaging \[MRI\], or positron emission tomography \[PET\])

Secondary

Measure	Time frame	Description
Disease persistence after 12-18 months from the primary treatment	12-18 months from the primary treatment	Rate of disease persistence after 12-18 months from the primary treatment, detected by any of the available imaging tools (neck sonography, radioiodine whole body scan, computed tomography \[CT\], magnetic resonance imaging \[MRI\], or positron emission tomography \[PET\])
Disease recurrence after 3, 5 and 10 years from the primary treatment	3, 5 and 10 years from the primary treatment	Rate of disease recurrence after 3, 5 and 10 years from the primary treatment, detected by any of the available imaging tools (neck sonography, radioiodine whole body scan, computed tomography \[CT\], magnetic resonance imaging \[MRI\], or positron emission tomography \[PET\])
Response to primary therapy	1, 3, 5 and 10 years after therapy	Response to primary treatment, evaluated according to the American Thyroid Association guidelines response to treatment: excellent response, biochemical incomplete response, indeterminate response, or structural incomplete response (combination of serum tumor markers and imaging tools, such as neck sonography, radioiodine whole body scan, computed tomography \[CT\], magnetic resonance imaging \[MRI\], or positron emission tomography \[PET\])
Response to secondary treatments	1, 3, 5 and 10 years after therapy	Response to secondary treatments, evaluated according to the American Thyroid Association guidelines response to treatment: excellent response, biochemical incomplete response, indeterminate response, or structural incomplete response (combination of serum tumor markers and imaging tools, such as neck sonography, radioiodine whole body scan, computed tomography \[CT\], magnetic resonance imaging \[MRI\], or positron emission tomography \[PET\])

Countries

Italy

Contacts

Primary ContactCosimo Durante, MD,PhD

cosimo.durante@uniroma1.it

Backup ContactGiorgio Grani, MD,PhD

giorgio.grani@uniroma1.it

Outcome results

None listed